Received Mar 20, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 1 | Unknown | PO / MO |
On the same day, the patient took the first dose of Vivotif and doxycycline; Case reference number US-BN-2024-002064 is a spontaneous case initially received from a pharmacist via Communications (reference number USBAV24-1359) on 13-Jun-2024 and concerns a patient of unknown demographics. The patient's medical history and concomitant medication details were not provided. On 11-Jun-2024, the patient took first dose of Vivotif (batch number: unknown), at an unknown dose, orally, for unknown indication. On the same day, the patient took a dose of Doryx (doxycycline, batch number: unknown), delayed release, at a dose of 60mg, for an unknown indication (explicitly coded as 'Product administration error'). The reporter wondered if the therapy should be stopped, wait for three days, and restart the series, or should the Vivotif be continued, and the doxycycline be stopped. At the time of the initial report, it was unknown if the patient experienced any adverse event due to the Vivotif vaccine. Non-significant follow up was downloaded from VAERS on 09-May-2025 included new reference number Administrative update performed within the case: Worldwide Unique Case Identification Number (WWID) updated from US-20240613-61f751 to [correct WWID], in accordance with ICH guidance on WWID formatting.; Reporter's Comments: A patient of unknown demographics took a dose of Doryx on the same day when the patient took first dose of Vivotif for unknown indication, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to the Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A patient of unknown demographics took a dose of Doryx on the same day when the patient took first dose of Vivotif for unknown indication, which is considered as product administration error. It was unknown if the patient experienced any adverse event due to the Vivotif vaccine. Product administration error is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error has been considered as not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None.
DORYX [DOXYCYCLINE]